GT BIOPHARMA, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.55 EUR | -86.52% |
|
-96.67% | -99.80% |
| Jun. 27 | GT Biopharma Says FDA Clears Investigational New Drug Application for Cancer Drug GTB-3650 | MT |
| Jun. 27 | GT Biopharma Shares Rise on FDA Clearance for Cancer-Drug Study | DJ |
Business Summary
The group has a portfolio of 3 products in clinical development phase (GTB-3550, GTB-3650 and GTB-5550; treatment of leukemia and solid tumors).
Managers
| Managers | Title | Age | Since |
|---|---|---|---|
Michael Breen
CEO | Chief Executive Officer | 61 | 21-01-12 |
Jeffrey Miller
PRN | Corporate Officer/Principal | - | 22-12-13 |
Members of the board
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 78 | 23-04-30 | |
Bruce Wendel
BRD | Director/Board Member | 70 | 20-11-10 |
Rajesh Shrotriya
BRD | Director/Board Member | 79 | 21-01-12 |
Michael Breen
CEO | Chief Executive Officer | 61 | 21-01-12 |
Share class
| Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
|---|---|---|---|---|---|
| Stock A | 0 | 96,230 | 0 | 0 | 89.34 % |
| Stock B | 1 | 2,156,651 | 2,012,830 ( 93.33 %) | 0 |
Company contact information
GT Biopharma, Inc.
8000 Marina Boulevard Suite 100
94005, Brisbane
+415 919 4040
http://www.gtbiopharma.com
Sector
| 1st Jan change | Capi. | |
|---|---|---|
| +62.66% | 854B | |
| +40.42% | 636B | |
| -4.37% | 361B | |
| +17.16% | 324B | |
| +9.87% | 301B | |
| +15.66% | 247B | |
| +4.21% | 230B | |
| +17.90% | 228B | |
| +14.86% | 177B |
- Stock Market
- Equities
- GTBP Stock
- GTBP Stock
- Company GT Biopharma, Inc.
